Skip to main content
Erschienen in: Breast Cancer 3/2013

01.07.2013 | Original Article

Identification of candidates for postmastectomy radiotherapy in patients with pT3N0M0 breast cancer

verfasst von: Yasushi Hamamoto, Shozo Ohsumi, Kenjiro Aogi, Shigemitsu Takashima, Shuichi Shinohara, Naomi Nakajima, Masaaki Kataoka

Erschienen in: Breast Cancer | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

There is still controversy concerning the indication of postmastectomy radiotherapy (PMRT) for pT3N0M0 breast cancer. To identify the candidates for PMRT in this subset, we investigated failure patterns, and searched for risk factors for isolated locoregional failure in pT3N0M0 breast cancer after mastectomy without PMRT.

Methods

Among 1,176 patients who received mastectomy without PMRT for untreated unilateral breast cancer between 1990 and 2002, 64 patients (5%) had pT3N0M0 breast cancer (age 30–81 years; median 52.5 years).

Results

Isolated locoregional failure as the initial failure occurred in three patients. For all 64 patients, the 8-year failure-free survival rate, the isolated locoregional failure-free rate, and the distant failure-free rate were 76, 93, and 82%, respectively. Incidence of isolated locoregional failure as the initial failure was 18% (2/11) for patients 40 years or younger and 2% (1/53) for patients older than 40 years. The 8-year isolated locoregional failure-free rates were 73% for patients 40 years or younger and 98% for patients older than 40 years (p = 0.0135).

Conclusion

Concerning pT3N0M0 breast cancer, incidence of isolated locoregional failure was comparatively low after mastectomy without PMRT. Routine use of PMRT for all pT3N0M0 patients seemed to be unacceptable. PMRT may be useful for younger patients because of the comparatively high incidence of isolated locoregional failure. Because of the small number of cases in our series, further studies are necessary to determine the usefulness of PMRT for younger patients with pT3N0M0 breast cancer.
Literatur
1.
Zurück zum Zitat Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337:949–55.CrossRefPubMed Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337:949–55.CrossRefPubMed
2.
Zurück zum Zitat Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen. Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353:1641–8.CrossRefPubMed Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen. Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353:1641–8.CrossRefPubMed
3.
Zurück zum Zitat Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97:116–26.CrossRefPubMed Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97:116–26.CrossRefPubMed
4.
Zurück zum Zitat Whelan TJ, Julian J, Wright J, Jadad AR, Levine ML. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol. 2000;18:1220–9.PubMed Whelan TJ, Julian J, Wright J, Jadad AR, Levine ML. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol. 2000;18:1220–9.PubMed
5.
Zurück zum Zitat Overgaard M. Overview of randomized trials in high risk breast cancer patients treated with adjuvant systemic therapy with or without postmastectomy irradiation. Semin Radiat Oncol. 1999;9:292–9.CrossRefPubMed Overgaard M. Overview of randomized trials in high risk breast cancer patients treated with adjuvant systemic therapy with or without postmastectomy irradiation. Semin Radiat Oncol. 1999;9:292–9.CrossRefPubMed
6.
Zurück zum Zitat Early Breast cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;366:2087–106. Early Breast cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;366:2087–106.
7.
Zurück zum Zitat Recht A, Edge SB, Solin LJ, Robinson DS, Estabrook A, Fine RE, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1539–69.PubMed Recht A, Edge SB, Solin LJ, Robinson DS, Estabrook A, Fine RE, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1539–69.PubMed
8.
Zurück zum Zitat Floyd SR, Taghian AG. Post-mastectomy radiation in large node-negative breast tumors: does size really matter? Radiother Oncol. 2009;91:33–7.CrossRefPubMed Floyd SR, Taghian AG. Post-mastectomy radiation in large node-negative breast tumors: does size really matter? Radiother Oncol. 2009;91:33–7.CrossRefPubMed
9.
Zurück zum Zitat Mignano JE, Gage I, Piantadosi S, Ye X, Henderson G, Dooley WC, et al. Local recurrence after mastectomy in patients with T3pN0 breast carcinoma treated without postoperative radiation therapy. Am J Clin Oncol. 2007;30:466–72.CrossRefPubMed Mignano JE, Gage I, Piantadosi S, Ye X, Henderson G, Dooley WC, et al. Local recurrence after mastectomy in patients with T3pN0 breast carcinoma treated without postoperative radiation therapy. Am J Clin Oncol. 2007;30:466–72.CrossRefPubMed
10.
Zurück zum Zitat Floyd SR, Buchholz TA, Haffty BG, Goldberg S, Niemierko A, Raad RA, et al. Low local recurrence rate without postmastectomy radiation in node-negative breast cancer patients with tumors 5 cm and larger. Int J Radiat Oncol Biol Phys. 2006;66:358–64.CrossRefPubMed Floyd SR, Buchholz TA, Haffty BG, Goldberg S, Niemierko A, Raad RA, et al. Low local recurrence rate without postmastectomy radiation in node-negative breast cancer patients with tumors 5 cm and larger. Int J Radiat Oncol Biol Phys. 2006;66:358–64.CrossRefPubMed
11.
Zurück zum Zitat Taghian AG, Jeong JH, Mamounas EP, Parda DS, Deutsch M, Costantino JP, et al. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2006;24:3927–32.CrossRefPubMed Taghian AG, Jeong JH, Mamounas EP, Parda DS, Deutsch M, Costantino JP, et al. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2006;24:3927–32.CrossRefPubMed
12.
Zurück zum Zitat Goulart J, Truong P, Woods R, Speers CH, Kennecke H, Nichol A. Outcomes of node-negative breast cancer 5 centimeters and larger treated with and without postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys. 2011;80:758–64.CrossRefPubMed Goulart J, Truong P, Woods R, Speers CH, Kennecke H, Nichol A. Outcomes of node-negative breast cancer 5 centimeters and larger treated with and without postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys. 2011;80:758–64.CrossRefPubMed
13.
Zurück zum Zitat Helintö M, Blomqvist C, Heikkilä P, Joensuu H. Post-mastectomy radiotherapy in pT3N0M0 breast cancer: is it needed? Radiother Oncol. 1999;52:213–7.CrossRefPubMed Helintö M, Blomqvist C, Heikkilä P, Joensuu H. Post-mastectomy radiotherapy in pT3N0M0 breast cancer: is it needed? Radiother Oncol. 1999;52:213–7.CrossRefPubMed
14.
Zurück zum Zitat McCammon R, Finlayson C, Schwer A, Rabinovitch R. Impact of postmastectomy radiotherapy in T3N0 invasive carcinoma of the breast: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2008;113(4):683–9.CrossRefPubMed McCammon R, Finlayson C, Schwer A, Rabinovitch R. Impact of postmastectomy radiotherapy in T3N0 invasive carcinoma of the breast: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2008;113(4):683–9.CrossRefPubMed
15.
Zurück zum Zitat Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst. 1998;90:1601–8.CrossRefPubMed Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst. 1998;90:1601–8.CrossRefPubMed
16.
Zurück zum Zitat Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Holmberg SB, et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol. 2003;21:1205–13.CrossRefPubMed Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Holmberg SB, et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol. 2003;21:1205–13.CrossRefPubMed
17.
Zurück zum Zitat Kyndi M, Overgaard M, Nielsen HM, Sørensen FB, Knudsen H, Overgaard J. High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c. Radiother Oncol. 2009;90:74–9.CrossRefPubMed Kyndi M, Overgaard M, Nielsen HM, Sørensen FB, Knudsen H, Overgaard J. High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c. Radiother Oncol. 2009;90:74–9.CrossRefPubMed
18.
Zurück zum Zitat Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J, Danish Breast Cancer Cooperative Group. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82b and c randomized studies. J Clin Oncol. 2006;24:2268–75.CrossRefPubMed Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J, Danish Breast Cancer Cooperative Group. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82b and c randomized studies. J Clin Oncol. 2006;24:2268–75.CrossRefPubMed
Metadaten
Titel
Identification of candidates for postmastectomy radiotherapy in patients with pT3N0M0 breast cancer
verfasst von
Yasushi Hamamoto
Shozo Ohsumi
Kenjiro Aogi
Shigemitsu Takashima
Shuichi Shinohara
Naomi Nakajima
Masaaki Kataoka
Publikationsdatum
01.07.2013
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 3/2013
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-011-0331-0

Weitere Artikel der Ausgabe 3/2013

Breast Cancer 3/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.